|
Balance Sheet Cash Flow Statement 130 Waverly St. Cambridge, MA 02139-4242 MA Tel. 617-444-6100 Fax 617-444-6680 |
Type: Public
On the web:
http://www.vpharm.com
Employees:
1,333
Employee growth: 15.9%
Vertex Pharmaceuticals represents the convergence of drug discovery technologies. The biotechnology company uses an integrated, multidisciplinary approach -- employing biophysics, computer-based modeling, and functional genomics -- to speed up the discovery and development of new drugs. It is focused primarily on the development of its lead candidate, telaprevir, an investigational treatment for hepatitis C. The company has a couple of other hepatitis C drugs in development, as well as possible treatments for cystic fibrosis, inflammatory disease, and cancer. Vertex, which was formed in 1989, has facilities in California and Massachusetts, and in the UK.
Key numbers for fiscal year ending December, 2008:
Sales: $175.5M
One year growth: (11.8%)
Net income: ($459.9)M
Officers:
Chairman and CEO: Matthew W. Emmens
EVP and CFO: Ian F. Smith
VP and CTO: Mark Murcko
Competitors:
Abbott Labs
Bristol-Myers Squibb
Roche Holding
